D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $12 from $24 and keeps a Buy rating on the shares after the company announced it is discontinuing the development of CT-0525 as part of a “strategic reprioritization. The firm reduced HERII cancers from its projections.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics announces restructuring, 34% workforce reduction
- Carisma Therapeutics Restructures Amid Strategic Refocus
- Carisma Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
- Carisma Therapeutics reports data from its CAR-M therapy
- Carisma Therapeutics reports Q3 EPS (31c), consensus (26c)